M&A Deal Summary

Amgen Acquires Alantos Pharmaceuticals Holding

On June 6, 2007, Amgen acquired life science company Alantos Pharmaceuticals Holding for 300M USD

Acquisition Highlights
  • This is Amgen’s 7th transaction in the Life Science sector.
  • This is Amgen’s 17th largest (disclosed) transaction.
  • This is Amgen’s 7th transaction in the United States.
  • This is Amgen’s 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2007-06-06
Target Alantos Pharmaceuticals Holding
Sector Life Science
Buyer(s) Amgen
Deal Type Add-on Acquisition
Deal Value 300M USD

Target

Alantos Pharmaceuticals Holding

Cambridge, Massachusetts, United States
Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company with a proprietary pipeline of small molecule drugs focused in the area of type II diabetes and osteoarthritis / inflammation. With locations in Cambridge, Massachusetts and Heidelberg, Germany, Alantos Pharmaceuticals employs 45 people.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States
Category Company
Founded 1980
Sector Life Science
Employees26,700
Revenue 28.2B USD (2023)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 7 of 21
Sector (Life Science) 7 of 20
Type (Add-on Acquisition) 7 of 20
State (Massachusetts) 2 of 3
Country (United States) 7 of 16
Year (2007) 2 of 2
Size (of disclosed) 17 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-06-04 Ilypsa

Santa Clara, California, United States

Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a pipeline of next-generation renal care pharmaceutical products.

Buy $420M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-01-24 BioVex Group

Woburn, Massachusetts, United States

BioVex Group, Inc. is a biotechnology company based in Woburn, Mass., with additional operations in Abingdon, UK. BioVex produces OncoVEX(GM-CSF), a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer.

Buy $1.0B
Mergr

Product

Company

Legal